Education

About the episodeIn this video, Prof Philip Hawkins (University College London, London, UK), addresses some important key questions surrounding amyloidosis, a…

BackgroundAmyloidosis represents a rare yet heterogeneous multi-system disorder associated with a grave prognosis and an enormous psycho-emotional strain on…

AimsHELIOS-A was a Phase 3, open-label study of vutrisiran, an RNA interference therapeutic, in patients with hereditary transthyretin (ATTRv) amyloidosis with…

BackgroundTransthyretin cardiac amyloidosis (ATTR‐CA) is a progressive and ultimately fatal cardiomyopathy. Biomarkers reflecting multiorgan dysfunction are of…

KEY POINTSTransthyretin amyloidosis typically presents with entrapment neuropathy, polyneuropathy or heart failure; some patients may experience autonomic…

Hereditary transthyretinexternal link, opens in a new tab amyloidosis is autosomal dominantexternal link, opens in a new tab and results from mutations in the…

Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is an underrecognized cause of heart failure due to misfolded wild-type transthyretin (TTRwt) myocardial…